Sarepta Gene Therapy Setbacks

News

Sarepta, gene therapy and Europe

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the approval of Elevidys, following mounting regulatory scrutiny and two recent patient deaths linked to the company's gene therapy.

BioPharma Dive · 2d

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

· 8d

Sarepta's Setback Deepens With Another Gene Therapy Fatality

3don MSN

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Devdiscourse7h

Health Sector Headlines: Shifts in Profits, Drug Developments, and Data-Sharing Innovations

HCA Healthcare raises 2025 profit forecast amidst insurance uncertainty while Centene anticipates a 2026 profitability boost ...

Barron's4y

Sarepta Stock Dropped 50% After Gene-Therapy Setback. What to Do Now.

Until Thursday, Sarepta Therapeutics led the race to prove that gene therapy could cure Duchenne muscular dystrophy, a genetic disorder that progressively weakens the muscles of children. Late ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results